Q3/2024 9/30/2024 EPS -0.310 ZacksConsensus -0.120 ActVsEst (0.190) - Miss
Inari Medical, Inc. (NARI)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
NARI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NARI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NARI alerts
High impacting Inari Medical, Inc. news events
Weekly update
A roundup of the hottest topics
NARI
News
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Truist Financial Co. from $46.00 to $50.00. They now have a "hold" rating on the stock.MarketBeat
- PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary EmbolismGlobeNewswire
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $71.00 to $74.00. They now have a "buy" rating on the stock.MarketBeat
- Inari Medical, Inc. (NASDAQ: NARI) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Inari Medical, Inc. (NASDAQ: NARI) had its price target raised by analysts at Piper Sandler from $50.00 to $52.00. They now have a "neutral" rating on the stock.MarketBeat
NARI
Earnings
- 7/30/24 - Miss
NARI
Sec Filings
- 10/31/24 - Form 4
- 10/31/24 - Form 4
- 10/29/24 - Form 144
- NARI's page on the SEC website